UBS Group
JUNO

UBS Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

UBS Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-80,000
Closed -$3.08M – 8170
2016
Q2 		$3.08M Buy
+80,000
New +$3.32M ﹤0.01% 2408

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

UBS Group's JUNO Position: Q1 2018 in Review

UBS Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 68,425 shares — an estimated $3.13M sold.

UBS Group first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $8.17M in Q1 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • UBS Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 68,425 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.13M.
  • UBS Group first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • UBS Group's Juno Therapeutics, Inc. position peaked at $8.17M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.